{"ok":true,"entity":{"id":"teva-pharmaceutical","name":"Teva Pharmaceutical Industries","entityType":"company","officialName":"Teva Pharmaceutical Industries Ltd.","canonicalName":"Teva Pharmaceutical Industries","displayName":"Teva Pharmaceutical Industries","category":"製薬企業（ジェネリック医薬品・革新的医薬品）","shortDescription":"Teva Pharmaceutical Industriesは、SEC EDGAR上でテルアビブに事業所を持つ製薬企業で、革新的医薬品、ジェネリック医薬品、バイオ医薬品の創出を掲げる。2026年第2四半期の売上は41億4,200万ドル、2026年の売上見通しは165億〜168.5億ドルと開示されている。2026年10月には米FDAが月1回皮下注射の統合失調症治療薬WELTRUZA（オランザピン）を承認したと報じられた。","primaryCluster":"pharmaceuticals","parentEntity":null,"verificationStatus":"draft","website":"https://www.tevapharm.com/","updatedAt":"2026-10-20T07:33:40.757Z","secondaryClusters":[],"alias":["Teva","テバ","Teva Pharmaceuticals"],"searchKeywords":["Teva","テバ","Teva Pharmaceutical Industries","ジェネリック医薬品","AUSTEDO","AJOVY","UZEDY","WELTRUZA","オランザピン","イスラエル 製薬"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}